Podcasts about ER

The 1995 tour was one of the most tumultuous for Pearl Jam in their history. Their Ticketmaster boycott was in full effect, so while shows were more affordable for their audience, tickets were tougher to acquire and venues were at a premium. Eddie at this time is dealing with struggles of being in the spotlight, and instead of opting to travel with the band, he spins records in a van driving from location to location on tour. There are historic shows that happen on this run like Red Rocks and Soldier Field, but everything comes to a head when they reach San Francisco. The night before the show, Ed comes down with a case of food poisoning and needs to take a trip to the ER. After getting IV fluids, he is still completely sick when it comes show time. However, he goes out there, makes it through seven songs and then walks off the stage no longer capable of playing. This episode looks back 30 years later after the infamous incident at Golden Gate Park. As luck would have it, Neil Young happened to be there that day originally slated to make a guest appearance prior to the Mirror Ball record's release three days later. While it was certainly a huge benefit to have him on hand in a desperate time of need, the crowd paid to see Eddie. They were restless throughout the entire set having to sit through unreleased songs off a brand new record in an unfathomable heat for San Francisco. For as incredible as the band's efforts were in this moment, winning over the crowd was a fruitless task. This is a jam packed episode with a lot to talk about. We'll cover the era and how the fallout from this show just narrowly avoided a break up, we'll talk about the crowd's reactions, Eddie's struggles and some of the oddities in song selection that included not one, but TWO versions of Rockin' In The Free World! We'll also invite our good friend, Mar Vigil, on to discuss what it was like to be there on that day. Visit the Concertpedia - http://liveon4legs.com Contact the Show - liveon4legspodcast@gmail.com Donate to the Show - http://patreon.com/liveon4legs

Alan Jackson attacks Hank Brennan's remarks on the Karen Read trial. Roberta answers some of Jackson's comment.Get access to exclusive content & support the podcast by becoming a Patron today! https://patreon.com/robertaglasstruecrimereportThrow a tip in the tip jar! https://buymeacoffee.com/robertaglassSupport Roberta by sending a donation via Venmo. https://venmo.com/robertaglassBecome a channnel member for custom Emojis, first looks and exclusive streams here: https://youtube.com/@robertaglass/joinThank you Patrons!JC, Lizzy D, Elizabeth Drake, Texas Mimi, Barb, Deborah Shults, Debra Ratliff, Stephanie Lamberson, Maryellen Sudol, Mona, Karen Pacini, Jen Buell, Marie Horton, ER, Rosie Grace, B. Rabbit, Sally Merrick, Amanda D, Mary B, Mrs Jones, Amy Gill, Eileen, Wesley Loves Octoberfest, Erin (Kitties1993), Anna Quint, Cici Guteriez, Sandra Loves GatsbyHannna, Christy, Jen Buell, Elle Solari, Carol Cardella, Jennifer Harmon, DoxieMama65, Carol Holderman, Joan Mahon, Marcie Denton, Rosanne Aponte, Johnny Jay, Jude Barnes, JenTheRN, Victoria Devenish, Jeri Falk, Kimberly Lovelace, Penni Miller, Jil, Janet Gardner, Jayne Wallace (JaynesWhirled), Pat Brooks, Jennifer Klearman, Judy Brown, Linda Lazzaro, Suzanne Kniffin, Susan Hicks, Jeff Meadors, D Samlam, Pat Brooks, Cythnia, Bonnie Schoeneman-Dilley, Diane Larsen, Mary, Kimberly Philipson, Cat Stewart, Cindy Pochesci, Kevin Crecy, Renee Chavez, Melba Pourteau, Julie K Thomas, Mia Wallace, Stark Stuff, Kayce Taylor, Alice, Dean, GiGi5, Jennifer Crum, Dana Natale, Bewildered Beauty, Pepper, Joan Chakonas, Blythe, Pat Dell, Lorraine Reid, T.B., Melissa, Victoria Gray Bross, Toni Woodland, Danbrit, Kenny Haines and Toni Natalie.

Seit es Menschen gibt, ist der Wald für sie von höchster Bedeutung. Er nährt, heilt, wärmt, schützt und bietet alles, was zum Überleben gebraucht wird. Im "hölzernen Zeitalter", das bis ins Jahr 1800 dauert, sorgt die Jagd für proteinreiche Nahrung, und das Holz liefert Brennmaterial sowie den Baustoff für Häuser und Werkzeuge. Von: Thomas Grasberger (BR 2025)

In den vergangenen Wochen haben Israel und die USA gezielte Luftangriffe auf iranische Atomanlagen und Schlüsselstrukturen des Regimes durchgeführt. Inzwischen gilt ein fragiler Waffenstillstand. War das Vorgehen der USA strategisch klug? Und was bedeuten die Angriffe für das iranische Regime und die Bevölkerung? In der aktuellen Folge des SPIEGEL-Podcasts »Acht Milliarden« spricht Host Juan Moreno mit dem stellvertretenden Leiter des SPIEGEL-Auslandsressorts, Maximilian Popp, und Susanne Kölbl, Autorin beim SPIEGEL, über die Motive der Akteure, die geopolitischen Folgen und die Frage, ob ein langfristiger Frieden überhaupt möglich ist. Mehr zum Thema: (S+) Prinz Turki Bin Faisal führte fast ein Vierteljahrhundert lang den saudi-arabischen Geheimdienst an. Er sieht in dem Krieg zwischen Israel und Iran nur Verlierer und warnt: Das iranische Atomprogramm sei nicht für immer gestoppt. Ein Interview von Maximilian Popp und Susanne Koelbl. https://www.spiegel.de/ausland/saudi-arabiens-ex-geheimdienstchef-turki-ueber-krieg-in-nahost-in-iran-schliessen-sich-jetzt-die-reihen-a-7ac1cefd-6a7c-4365-a3d8-2ed1b0fd1b93 (S+) Die Straße von Hormus ist nicht das einzige Nadelöhr, dessen Blockade die weltweite Erdöl- und Erdgasversorgung gefährden würde. Der SPIEGEL zeigt die riskantesten Passagen der Weltmeere. Von Susanne Götze und Anna-Lena Kornfeld. https://www.spiegel.de/wissenschaft/iran-israel-konflikt-was-die-strasse-von-hormus-und-andere-nadeloehre-fuer-die-energiemaerkte-bedeuten-a-8c14508d-6ef5-4f88-a8e8-73184cf5246d Abonniert »Acht Milliarden«, um die nächste Folge nicht zu verpassen. Wir freuen uns, wenn ihr den Podcast weiterempfehlt oder uns eine Bewertung hinterlasst.+++ Alle Infos zu unseren Werbepartnern finden Sie hier. Die SPIEGEL-Gruppe ist nicht für den Inhalt dieser Seite verantwortlich. +++ Den SPIEGEL-WhatsApp-Kanal finden Sie hier. Alle SPIEGEL Podcasts finden Sie hier. Mehr Hintergründe zum Thema erhalten Sie mit SPIEGEL+. Entdecken Sie die digitale Welt des SPIEGEL, unter spiegel.de/abonnieren finden Sie das passende Angebot. Informationen zu unserer Datenschutzerklärung.

Der 72-Jährige hat in seinen knapp 20 Jahren als Präsident schon so ziemlich alle Facetten des Fussballs erlebt, die schönen und die weniger schönen. Aber eine derart turbulente Saison wie zuletzt ist auch für Canepa nicht alltäglich.Er äussert sich zu seiner Vision des FCZ und warum er den Club weiterhin auf einem «guten Weg». Er spricht über Sportchef Milos Malenovic und dessen teils «rigoroses» Vorgehen. Über die Trennung von Spielern wie Antonio Marchesano und Mirlind Kryeziu. Und er sagt, dass sich im Fall von Spieler Benjamin Mendy in diesem Sommer doch noch etwas tun könnte.Die Themen:00:00 Intro02:03 Der Konflikt mit Thomas Schifferle06:25 Fast 20 Jahre als Präsident11:56 Der gewaltige Kader-Umbruch22:21 Die Abgänge von Marchesano und Kryeziu28:40 Schirm-Wurf und Schiri-Schelte33:02 Der Fall Benjamin Mendy37:14 Sportchef Milos Malenovic46:33 Trainer Mitchell van der Gaag50:55 Übernimmt Malenovic den FCZ?01:01:26 Die rechtswidrige KurvensperreTickets für den Live-Podcast mit Imke Wübbenhorst und Fabienne Humm am 30. Juni in der Amboss Rampe in Zürich: Zum Ticketshop In der Dritten Halbzeit wird über den Schweizer Fussball diskutiert.

Er was geen koers de afgelopen dagen!! Alhoewel, het Nederlands kampioenschap tijdrijden, noem het maar niks. Maar het was niet zo alomvattend als de afgelopen weken en al helemaal niet zo goed gevuld als het de komende maand gaat zijn. Er wordt gerust, getraind, genoten. Een mooi moment voor ons om de postzak weer eens te legen en de laatste wielernieuwtjes uit te diepen. Ook blikken we vooruit naar het NK, wat een waar sprintersbal belooft te worden. Viel spass! Jullie kunnen ons weer LIVE zien deze Tour de France!: 18 juli - Tour de Dance Reprise in Tivoli, voorafgaand doen we een live podcast (vanaf ongeveer 21:30 uur) daarna feessie, voor gratis! Wees op tijd want vol=vol! 20 juli - Etappe kijken en daarna podcast bij PONG te Amsterdam West! Ticketlinkje volgt nog, Vrienden van de Show krijgen voorrang!

Der Deutsche Mieterbund kritisiert die heute beschlossene Mietpreisbremse. Er fordert eine Verschärfung des Instruments.

In dieser Episode des Kassenzone-Podcasts blicke ich zusammen mit Tarek Müller auf die K5-Konferenz zurück. Nach der Bekanntgabe der Thesen zur Zukunft des E-Commerce diskutieren wir den aktuellen Status von Unternehmen wie About You und Zalando. Wir hinterfragen, ob Online-Shops mittlerweile die Dieselmotoren der Branche sind oder ob sie vielmehr eine zukunftsfähige Entwicklung besitzen, vergleichbar mit einem Elektroantrieb. Unter anderem diskutieren wir die Achse zwischen E-Commerce-Playern, insbesondere die drei Archetypen: Händler, Marke und Marktplatz-Trader. Ich erkläre, wie diese Archetypen unterschiedlich auf die Herausforderungen reagieren, die mit Themen wie KI und Community Engagement verbunden sind. Es wird klar, dass jede These und jedes Konzept nicht universell anwendbar ist, sondern vielmehr differenziert betrachtet werden muss. Tarek gibt Einblicke in den Fusionsprozess mit Zalando und die Herausforderungen, die dies mit sich bringt. Der langwierige Prozess der Kartellfreigabe wird thematisiert, und ich erfahre, welche strategischen Überlegungen hinter der Zusammenlegung der Logistik und der Payment-Infrastruktur stehen. Dabei wird das Potenzial einer Effizienzsteigerung und einer besseren Marktmacht der fusionierten Unternehmen deutlich. Die Diskussion über Margen im E-Commerce ist ebenso spannend. Tarek erläutert, wo sich Einsparpotentiale verstecken und wie die Branche durch eine Konsolidierung neue Perspektiven gewinnen kann. Er zieht auch Parallelen zwischen den großen Online-Händlern und den Herausforderungen, mit denen kleinere Marken konfrontiert sind. Trotz niedriger Margen im E-Commerce gibt es Überschneidungen und Potenzial für eine positive Entwicklung. KI Gipfel: https://www.eventbrite.de/e/der-deutsche-ki-gipfel-2025-treffpunkt-fur-macher-tickets-1286176702139 EXCITE Berlin: https://spryker.com/events/excite-2025/ Partner in der Folge: https://linktr.ee/kassenzone Community: https://kassenzone.de/discord Feedback zum Podcast? Mail an alex@kassenzone.de Disclaimer: https://www.kassenzone.de/disclaimer/ Kassenzone” wird vermarktet von Podstars by OMR. Du möchtest in “Kassenzone” werben? Dann https://podstars.de/kontakt/?utm_source=podcast&utm_campaign=shownotes_kassenzone Alexander Graf: https://www.linkedin.com/in/alexandergraf/ https://twitter.com/supergraf Youtube: https://www.youtube.com/c/KassenzoneDe/ Blog: https://www.kassenzone.de/ E-Commerce Buch 2019: https://amzn.eu/d/5Adc1ZH Plattformbuch 2024: https://amzn.eu/d/1tAk82E

Endlich findet Snoof einen Freund: Waldtroll Popoff. Er erklärt dem Riesenzwerg den Weg zu Prinzessin Kleinklein. Hoffentlich schrumpft sie Snoof sofort in einen kleinen Zwerg. Aus der OHRENBÄR-Hörgeschichte: Snoofs Reise ins Land der goldenen Pilze (Folge 6 von 7) von Janine Lüttmann. Es liest: Robert Missler. ▶ Mehr Hörgeschichten empfohlen ab 6: https://www.ohrenbaer.de/podcast/empfohlen-ab-6.html ▶ Mehr Infos unter https://www.ohrenbaer.de & ohrenbaer@rbb-online.de

Der Weg von Thomas in die Süchte beginnt schon mit neun Jahren. Damals begann er Klebstoff zu schnüffeln. Danach folgten Alkohol, Marihuana und Amphetamine. Mittlerweile ist er clean und geht ganz offen mit diesem Thema um. Er hält Präventionsvorträge an Schulen, um jungen Menschen klarzumachen, wie leicht es ist, in die Sucht abzurutschen. Mit Martina Straten spricht er über seinen Weg, über Alltags­süchte, die wir alle kennen, und über die Gefahren, in die man sich schon als Kind begeben kann.

ABC News medical correspondent and emergency room physician Dr. Darien Sutton joins Sara Haines for a special episode of "Behind the Table." The duo dives into the public debate over vaccines, the "MAHA" movement and the importance of communication in medicine. Then, Dr. Sutton reflects on his journey bringing his medical expertise to ABC News and his most poignant memories from working in the ER. Have a question or want advice from Brian or a co-host? Call or text us at (917) 960-3037 or leave us a message here: https://woobox.com/kaoojs. Messages may be used on a future podcast. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Karen Read jurors are talking & their interviews are quite telling! Shenagians seemed to be going on during deliberations! Let's talk about it! Also, Karen Read's father is talking God and Karen Read's brother seems to be giving a subtle middle finger up to the O'Keefe family!Get access to exclusive content & support the podcast by becoming a Patron today! https://patreon.com/robertaglasstruecrimereport Throw a tip in the tip jar! https://buymeacoffee.com/robertaglass Support Roberta by sending a donation via Venmo. https://venmo.com/robertaglass Become a channnel member for custom Emojis, first looks and exclusive streams here: https://youtube.com/@robertaglass/joinShow Notes:Innocence Fraud Watch "(UPDATING) Some Insight Into The Many Faces Of Juror #11 – Conceited Gaslighter, Attention Seeker & Depraved Con-Artist Paula Prado AKA Paula Serageldin AKA Paula Prado Serageldin"- https://theerrorsthatplaguethemiscarriageofjusticemovement.home.blog/2025/06/20/some-insight-into-the-many-faces-of-juror-11-aka-paula-prado-aka-paula-serageldin-aka-paula-prado-serageldin/ NBC 10 WJR "No one could prove..." -https://www.youtube.com/watch?v=6_c9-Kfc9HQ&t=4sNBC 10 WJR "Karen Read's brother, father..." -https://www.youtube.com/watch?v=uhsOZGqZwt8&t=3sThank you Patrons!JC, Lizzy D, Elizabeth Drake, Texas Mimi, Barb, Deborah Shults, Debra Ratliff, Stephanie Lamberson, Maryellen Sudol, Mona, Karen Pacini, Jen Buell, Marie Horton, ER, Rosie Grace, B. Rabbit, Sally Merrick, Amanda D, Mary B, Mrs Jones, Amy Gill, Eileen, Wesley Loves Octoberfest, Erin (Kitties1993), Anna Quint, Cici Guteriez, Sandra Loves GatsbyHannna, Christy, Jen Buell, Elle Solari, Carol Cardella, Jennifer Harmon, DoxieMama65, Carol Holderman, Joan Mahon, Marcie Denton, Rosanne Aponte, Johnny Jay, Jude Barnes, JenTheRN, Victoria Devenish, Jeri Falk, Kimberly Lovelace, Penni Miller, Jil, Janet Gardner, Jayne Wallace (JaynesWhirled), Pat Brooks, Jennifer Klearman, Judy Brown, Linda Lazzaro, Suzanne Kniffin, Susan Hicks, Jeff Meadors, D Samlam, Pat Brooks, Cythnia, Bonnie Schoeneman-Dilley, Diane Larsen, Mary, Kimberly Philipson, Cat Stewart, Cindy Pochesci, Kevin Crecy, Renee Chavez, Melba Pourteau, Julie K Thomas, Mia Wallace, Stark Stuff, Kayce Taylor, Alice, Dean, GiGi5, Jennifer Crum, Dana Natale, Bewildered Beauty, Pepper, Joan Chakonas, Blythe, Pat Dell, Lorraine Reid, T.B., Melissa, Victoria Gray Bross, Toni Woodland, Danbrit, Kenny Haines and Toni Natalie.

Philipp Justus zählt zu den wichtigsten deutschsprachigen Managern der US-Tech-Riesen. Im OMR Podcast erzählt der Google-Deutschland-Chef, für welchen Job er von Gründer-Legende Oliver Samwer abgeworben wurde. Er blickt auf die Veränderungen durch KI und sagt, warum er nicht glaubt, dass diese eine Gefahr für die Zukunft der Google-Suche sind. Und er verrät, welchen Content eines weltbekannten Youtubers er gerne verfolgt.

Das neue Vertragspaket mit der EU liegt auf dem Tisch. Nun spricht zum ersten Mal der Chefunterhändler der Schweiz darüber. Patric Franzen gibt Einblicke in die Verhandlungstaktik. Nach Vorsondierungen zwischen der Schweiz und der EU hat Patric Franzen im Frühling 2024 die Verhandlungen mit der EU aufgenommen. Vieles war da schon abgemacht. Wie gross war sein Spielraum überhaupt? Welche Druckmittel hatte er in der Hinterhand? Wo ist ihm die EU entgegengekommen, wo nicht? Im Tagesgespräch gibt Franzen Einblicke hinter die Kulissen der Verhandlungen und präzisiert zwei umstrittene Punkte: Die dynamische Rechtsübernahme und die Schutzklausel. Er ist zu Gast bei Simone Hulliger.

1985 kam Karamba Diaby zum Studieren aus dem Senegal in die DDR. Er studierte in Halle an der Saale und promovierte über die Schwermetallbelastung hallescher Schrebergärten. Von 2013 bis 2025 saß er für die SPD im Bundestag.

US-Geheimdiensterkenntnissen zufolge, über die die «New York Times» und CNN berichteten, könnten die US-Angriffe das iranische Atomprogramm möglicherweise nur um wenige Monate zurückgeworfen haben. Donald Trump widersprach dieser Einschätzung am Mittwoch während des Nato-Gipfels in Den Haag.Der US-Präsident sprach von «Fake News» und betonte, man habe die Atomanlagen «vollständig zerstört». In Den Haag sagte er vor Journalisten: «Ich glaube, es war eine totale Auslöschung.» Er sprach von einer «perfekten Operation». Den beiden Medien CNN und «New York Times» unterstellte er, die Regierung schlecht aussehen lassen zu wollen.Gemäss einer Umfrage von CNN lehnen 56 Prozent der US-Bürger die Angriffe ab, 79 Prozent befürchten eine Eskalation, bei der amerikanische Zivilisten und Soldaten zu Schaden kommen könnten. Eine Haltung, die auch bei Trumps Anhängerinnen und Anhängern stark verbreitet ist: Ihr Idol hatte versprochen, dass die sogenannten Forever-Wars, die nie enden wollenden Kriege mit US-Beteiligung, vor allem im Nahen Osten, zu beenden, und vor allem keine neuen zu beginnen. Entsprechend äusserte sich Trump vor seinem Abflug nach Europa: «Wir haben zwei Länder, die so lange und so hart gekämpft haben, dass sie nicht wissen, was zum Teufel sie da tun.»In Den Haag kündigte Trump neue Gespräche zwischen den USA und dem Iran an. «Vielleicht unterzeichnen wir ein Abkommen, ich weiss es nicht.» Trump sagte weiter, er sei eigentlich nicht sonderlich an der Wiederaufnahme von Verhandlungen mit dem Iran interessiert. «Es ist mir egal, ob ich ein Abkommen habe oder nicht», betonte der US-Präsident. «Sie werden es sowieso nicht tun», sagte Trump mit Blick auf ein mögliches Streben des Iran nach einer Atomwaffe. «Die haben genug.»Was waren die Motive hinter dem Militärschlag gegen den Iran? Was sagt der Waffenstillstand über Trumps Einfluss im Nahen Osten aus? Und wie reagieren die Mitglieder des US-Kongresses? Darüber unterhält sich Christof Münger, Leiter des Ressorts International, mit Tina Kempin Reuter, Politikwissenschaftlerin in Birmingham, Alabama, in einer neuen Folge des USA-Podcasts «Alles klar, Amerika?». Mehr USA-Berichterstattung finden Sie auf unserer Webseite und in den Apps. Den «Tages-Anzeiger» können Sie 3 Monate zum Preis von 1 Monat testen: tagiabo.ch.Feedback, Kritik und Fragen an: podcasts@tamedia.ch

Überschwemmungen, Pandemien und kriegerische Auseinandersetzungen - die Bedrohungen nehmen zu. Heißt es da nicht einmal mehr: be prepared? Vielleicht ist es an der Zeit, den sogenannten „Preppern“ mit etwas mehr Verständnis zu begegnen und sich zu fragen, ob man selbst ausreichend vorbereitet ist für einen wie auch immer gearteten Ernstfall. Jenseits von fanatischen Apokalyptikern gibt es viele Menschen, die sich ernsthaft mit Katastrophenschutz, Frühwarnsystemen und Vorratshaltung beschäftigen. Und doch stellt sich die Frage, ob man beruhigt leben kann, wenn man die Bedrohung immer im Kopf hat. Darüber reden wir mit dem Prepper Philipp Jakubowski, mit Mischa Luy, Sozialwissenschaftler und Autor von „Die erwartete Katastrophe“, mit dem Architekten Joachim Schulze vom Projekt "emergenCITY" der TU Darmstadt und dem Sozialpsychologen Jan A. Häusser von der Universität Gießen. Podcast-Tipp: ARD - Weltspiegel Finnland: Volkssport Preppen - Und was macht Deutschland? Vorräte anlegen, Wasser bunkern, Schutzräume bauen - was in Deutschland lange als übertrieben galt, ist in Finnland längst Alltag. Dort ist "Preppen" Teil der Sicherheitskultur. Doch wie gut ist eigentlich Deutschland auf den Ernstfall vorbereitet? Was tun, wenn der Strom ausfällt, der Supermarkt leer ist oder ein militärischer Angriff droht? ARD-Korrespondentin Sofie Donges war für den Weltspiegel in Finnland unterwegs - und hat mit Menschen gesprochen, die sich auf alle Szenarien vorbereiten. Außerdem hat sie sich einen der über 50.000 finnischen Schutzräume von innen angeschaut. Und: Wie ist die Lage in Deutschland? Darüber sprechen wir mit Norbert Gebbeken, Professor an der Universität der Bundeswehr München und Leiter des Forschungszentrums RISK. Er erklärt, warum hierzulande kein einziger öffentlicher Bunker einsatzbereit ist - und was jetzt passieren muss. https://www.ardaudiothek.de/episode/weltspiegel-podcast/finnland-volkssport-preppen-und-was-machen-die-deutschen/ard/14740187/

Körper, Gefühl und Gesangstechnik wirken zusammen, wenn Stelios Chatziktoris mit seinem HXOS Chor probt. Der Gesangspädagoge und Tenor schwört auf die Kombination von Stimm- und Bewegungstraining. Er ist überzeugt: Singen macht glücklich und gesund. Führer, Susanne www.deutschlandfunkkultur.de, Im Gespräch

In dieser Episode des Podcasts besuche ich Christian Grotholt, den CEO von 2G. 2G ist seit über 30 Jahren im Bereich der Kraft-Wärme-Kopplung (KWK) tätig und hat sich als globaler Pionier und Marktführer etabliert. Wir diskutieren ausführlich über die innovative Technologie der KWK, die sich durch ihre dezentrale Anwendung auszeichnet und in der aktuellen Energiepolitik oft zu Unrecht in den Hintergrund gedrängt wird. Christian teilt spannende Einblicke in die Umsatzentwicklung von 2G, die sich in den letzten Jahren auf 370 Millionen Euro beliefen. Er erklärt, dass die Nachfrage nach dieser Technologie in den kommenden zwei Jahrzehnten weiter stark wachsen wird, da große Unternehmen der Öl- und Gasindustrie gezwungen sind, ihre Strategien zu überdenken. Diese Veränderungen im Markt schaffen Raum für neue Akteure – wie beispielsweise die Firmen aus den Bereichen Solar- und Windenergie sowie KWK-Unternehmen – die von den sinkenden Importkosten für fossile Brennstoffe profitieren werden. Wir vertiefen uns in die verschiedenen Segmente der Kraft-Wärme-Kopplung, insbesondere in Blockheizkraftwerke, die elektrische und thermische Energie effizient erzeugen können. Christian erläutert, wie diese Anlagen nicht nur zur Stromversorgung, sondern auch zur Bereitstellung von Wärme eingesetzt werden können. Er führt einige interessante Anekdoten aus der Zusammenarbeit mit Biogasanlagen an, die aufzeigen, wie wichtig es ist, Abwärme durch KWK-Anlagen sinnvoll zu nutzen, anstatt sie ungenutzt zu lassen. Dabei betont er, dass die Integration von Wasserstoff als Energieträger eine wichtige Brückentechnologie darstellt, um die Herausforderungen der Energiewende zu meistern. Auch die politische Landschaft in Deutschland spielt eine Rolle in unserem Gespräch. Wir diskutieren die sich abzeichnenden Herausforderungen in der Energiepolitik, insbesondere die Notwendigkeit eines integrativen Ansatzes zur Umsetzung der Energiewende. Christian äußert sich zu den Ansätzen, die verbunden werden sollten, um die Potenziale der KWK und der erneuerbaren Energien voll auszuschöpfen und die verschiedenen Segmente besser miteinander zu vernetzen. Er beschreibt zudem die internationalen Märkte und welche Länder – wie Dänemark und das Vereinigte Königreich – in Sachen KWK und erneuerbare Energien eine Vorreiterrolle übernehmen. Dänemark hebt insbesondere hervor, wie frühzeitig man kanalisierte Wärmeversorgungssysteme etabliert hat, was einen erheblichen Wettbewerbsvorteil darstellt. Wir ziehen Parallelen zur deutschen Infrastruktur und besprechen, wie wichtig es ist, bestehende Systeme hinsichtlich ihrer Leistungsfähigkeit an die modernen Anforderungen anzupassen. Ein weiteres zentrales Thema ist der Wasserstoff. Christian erklärt die aktuellen Herausforderungen und Perspektiven zur Wasserstoffnutzung in KWK-Anlagen. Wir diskutieren die Notwendigkeit der Entwicklung von Elektrolyseuren und die damit verbundenen Hürden, die einer breiteren Implementierung im Weg stehen. Zudem betrachtet er die Trends im Energieversorgungsmarkt, insbesondere die Nachfrage und das Wachstum der dezentrale Energieerzeugung. Die Energiethemen erscheinen regelmäßig im Energiezone Podcast. Diesen findet ihr auf www.energiezone.org bzw. in allen relevanten Podcastkanälen. Partner in der Folge: https://linktr.ee/kassenzone Community: https://kassenzone.de/discord Feedback zum Podcast? Mail an alex@kassenzone.de Disclaimer: https://www.kassenzone.de/disclaimer/ Kassenzone” wird vermarktet von Podstars by OMR. Du möchtest in “Kassenzone” werben? Dann https://podstars.de/kontakt/?utm_source=podcast&utm_campaign=shownotes_kassenzone Alexander Graf: https://www.linkedin.com/in/alexandergraf/ https://twitter.com/supergraf Youtube: https://www.youtube.com/c/KassenzoneDe/ Blog: https://www.kassenzone.de/ E-Commerce Buch 2019: https://amzn.eu/d/5Adc1ZH Plattformbuch 2024: https://amzn.eu/d/1tAk82E

Im christlichen Leben ist der Kampf mit der Welt einer von drei geistlichen Hauptkonflikten – neben dem Fleisch und dem Teufel. R. C. Sproul beleuchtet in diesem Text besonders die subtile, aber kraftvolle Verführung der Welt: ein gefallenes Wertesystem, das den Menschen von Gott ablenkt. 1. Keine neutrale Zone Wir leben mitten im geistlichen Kriegsgebiet. Die Welt ist nicht bloß Bühne, sondern Schlachtfeld. Jeder Ort unseres Lebens ist betroffen – es gibt keinen neutralen Raum. 2. Die Verführungskraft der Welt Die Welt wirkt auf uns durch Sichtbares, Nahes, Begehrenswertes – und verdeckt damit den Blick auf das Ewige. Der ständige Druck zur Anpassung – oft getrieben von dem Wunsch nach Beliebtheit – stellt Christen vor die Herausforderung: Menschen gefallen oder Gott? 3. Der Zeitgeist des Säkularismus Die Welt von heute ist stark säkular geprägt. Sie orientiert sich am Jetzt und blendet die Ewigkeit aus. Jesus ruft jedoch zu einer Perspektive über das Sichtbare hinaus auf: »Sammelt euch Schätze im Himmel« (Mt 6,20). 4. Berufung zur Unangepasstheit Christen sind aufgerufen, sich nicht diesem Weltlauf anzupassen (Röm. 12,2). Diese Unangepasstheit ist nicht bloß äußerlich oder rebellisch, sondern Ausdruck einer inneren Erneuerung durch den Geist Gottes – einer neuen Gesinnung. 5. In der Welt, nicht von der Welt Christen sollen nicht fliehen, sondern in der Welt leben und dienen. Gott hat die Welt nicht aufgegeben. Er ruft uns, sie mit dem Licht des Evangeliums zu durchdringen – mit Klarheit, Mut und geistlicher Reife. 6. Reifung durch Rückzug – und Rückkehr Wie Mose oder Paulus brauchen Gläubige Zeiten des Rückzugs, um geistlich zu reifen. Doch wahres Wachstum zeigt sich darin, dass man wieder in die Welt hineingeht – diesmal verwandelt und bereit, Christus mitten im Alltag zu bezeugen. Kernbotschaft: Die Welt wird immer versuchen, uns zu formen. Doch echte Christusnachfolge bedeutet, innerlich erneuert zu leben – nicht um uns selbst willen, sondern um Seinetwillen. Dann können wir als Lichter in einer dunklen Welt leuchten (Phil 2,14–16). https://voh-missionswerk.de/blog/der-kampf-mit-der-welt/

In dieser Bauchdetektiv-Geschichte erfährst du:warum dir Intuitiv Essen ermöglicht, zu dir zurückzukommen und einfach “du selbst” zu sein.wie du mit der Angst vor Gewichtszunahmen und dem gesellschaftlichen Druck abzunehmen umgehen kannst.wie du mit dem Intuitiven Essen am besten startest.Links:Alle Infos zu Dr. Antonie Post:Buch “Intuitiv essen, gesünder werden, besser leben” https://www.penguin.de/buecher/antonie-post-intuitiv-essen-gesuender-werden-besser-leben/paperback/9783517103549Podcast “Iss doch, was du willst!”: https://antoniepost.de/podcast/Bitte-nicht-Wiegen-Karten: https://antoniepost.de/bitte-nicht-wiegen/4x10 Antworten: https://antoniepost.de/antworten-fettphobie-bodyshaming/ Alle Infos zur Bauchdetektivin Daniela:WH Vortrag “Dick=krank: Mythos oder Wahrheit?”: https://myablefy.com/s/bauchdetektivin/wissenshappen-dick-krankWebsite: https://www.danielamulle.at/Instagram: https://www.instagram.com/bauchdetektivin/YouTube-Kanal: https://www.youtube.com/@bauchdetektivin_danielamulleDisclaimer:Bitte vergiss nicht: Ein Podcast ersetzt natürlich nie eine individuelle medizinische oder psychische Gesundheitsberatung. Er stellt auch keine TherapeutIn-PatientIn-Beziehung dar, sondern dient ausschließlich zu Informations- und Bildungszwecken.

Veel singles omschrijven zichzelf als ‘laatbloeier’. En dat label zit lang niet altijd even comfortabel. Het idee van ‘achterlopen op de rest’ begint vaak al in de wieg, weet Lizz uit ervaring. Maar ook op relatievlak hebben wij ons lang laatbloeiers of muurbloempjes gewaand. Wat nou als je op ‘latere’ leeftijd geen ervaring hebt met seks, zoenen of een vaste relatie? Bij veel mensen gaat laatbloeierschap gepaard met veel schaamte, maar daar maken wij in deze aflevering graag een eind aan! Er is niks mis mee en wij helpen je graag om je inner bloem te ownen.

John Luke finally spills the tea on what it was really like growing up in Willie's house and in front of the cameras—including the classic parenting fail that landed him in the ER with a rabies scare. Uncle Si cracks up over Willie's brutal nicknames for his own grandkids, and Martin recalls the moment he witnessed John Luke's official entry into manhood, which turned into an unofficial (and unfortunate) family job. John-David loves seeing John Luke and Mary Kate live out their modern “Little House on the Prairie” lifestyle. Plus: John-Luke's iconic “Bumblebee Tuna” scene and the secret comedy training behind it! Duck Call Room episode #459 is sponsored by: https://nutrafol.com — Get $10 off your first month's subscription and free shipping when you use promo code DUCK! For 10% off your order, go to https://pestie.com/duck For 20% off your order, head to https://Reliefband.com and use code DUCK. - Learn more about your ad choices. Visit megaphone.fm/adchoices

Munaf Manji and Griffin Warner break down MLB Tuesday. Best bets as always. The June MLB betting preview episode from RJ Bell's Dream Podcast, hosted by Munaf Manji and Griffin Warner, covers 13 games with available lines, diving into team form, pitching matchups, and betting leans. Missing initially were lines for Dodgers-Rockies and Rangers-Orioles, though the latter appeared late in the episode. They open noting Munaf's bounce-back 5–1 week and Griffin chasing closely behind in season-long picks. The first matchup—Blue Jays vs. Guardians—features even odds. Griffin sees value in whoever becomes the underdog. Munaf highlights Logan Allen's stark ERA split: 6.18 in day games, 2.79 at night. The A's-Tigers game sees Tigers favored at -275. Griffin critiques the price despite Skubal's Cy Young form. Munaf adds that Tigers are 20–5 straight up in series openers and 11–1 at home. Yankees vs. Reds features rookie Chase Burns in his debut against Carlos Rodon. Griffin notes the Yankees are built better for the park, while Munaf explains Rodon's recent regression—12 ER in June compared to 5 in May. Braves-Mets has Strider returning, though Griffin questions his sharpness. Munaf notes Monteas' poor historical outings vs. the Braves and leans Strider, citing a recent quality start against the Mets. In D-backs vs. White Sox, Ryan Nelson's 1.87 ERA at night vs. 10.95 in the day impresses Munaf, while Griffin mocks the Sox as a “Double-A team.” For Pirates-Brewers, Peralta is dominant at home (6–1 SU), prompting a team total under lean from Munaf. Griffin applauds Milwaukee's base-stealing and efficiency. Mariners-Twins rematch Castillo vs. Paddack: both had elite starts earlier this month. Munaf likes the under (8.5), while Griffin again hails Cal Raleigh's ("Big Dumper") surge. Rays-Royals sees Griffin supporting Bubich, especially given Tampa's recent inconsistency. Munaf notes Taj Bradley's 13 ER in two starts. Cubs-Cardinals analysis finds Griffin liking STL as a home dog, with Munaf highlighting McGreevy's sub-1.00 WHIP and 2–1 team record in his starts. In Phillies-Astros, both agree Suarez and Valdez are elite. Munaf reveals Valdez's 6–1 under trend at home, while Suarez is 3–0–1 to the under on the road. Under 7.5 is Munaf's best bet. Red Sox vs. Angels pits Crochet's 2.20 ERA and 125 Ks against inconsistent Tyler Anderson. Griffin leans Angels as a value play; Munaf backs Boston's run line. Nationals-Padres gets light treatment—Williams has a 5.54 ERA and Padres are favored. Munaf suggests SD's first-five team total over. Giants-Marlins rounds out the card with Verlander's return. Griffin hesitates to back either starter but leans under unless conditions are hot. Munaf prefers the Giants, questioning Miami's bullpen. A late line appears for Rangers-Orioles. Griffin picks Baltimore ML (-130) as his best bet, citing Charlie Morton's improved form and Texas' offensive struggles. Munaf agrees, referencing Morton's 6 IP, 2 ER outing vs. TEX last year. The episode concludes with Griffin plugging a promo code (RBI20) for discounted betting picks access and teasing more comedic yet informative breakdowns through summer. Learn more about your ad choices. Visit megaphone.fm/adchoices

An Ottawa mom had to take her son to the ER when he came home from class with heat exhaustion; she says school administrators need to do a better job of keeping students safe. Before the shaky ceasefire with Iran, Israel attacked a prison in Tehran that houses political prisoners -- and today, friends and family are still waiting on news about their loved ones. The Democratic primary for mayor falls on New York City's hottest day in years -- and a strategist says the close race between an establishment moderate and outsider progressive could point to where the party heads next.Two Nigerian communities are taking oil giant Shell to court over longstanding pollution caused by spills -- which they say has infiltrated their drinking water. We hear from an artist in the UK about her project that could take decades: drawing every pub in London. A British nightclub becomes the site of a sinister mystery -- when someone leaves behind a surprisingly large, and just surprising, sausage.As It Happens, the Tuesday Edition. Radio that loves a club banger.

We present a patron Bonus  ★ Support this podcast on Patreon ★

When Amee Devani watched her mother battle colorectal cancer in Kenya, she witnessed firsthand the stark reality of healthcare inequity. That experience would reshape her entire career trajectory—from investment banking at UBS to founding a digital health startup that's revolutionizing how hospitals manage post-acute care. "I faint when they take my blood," Amee admits with characteristic candor. Yet today, as CEO and Co-founder of WellBeam, she's tackling one of healthcare's most persistent problems: the black box of care that swallows patients after hospital discharge. This conversation with host Laurie McGraw reveals how a chance meeting on a Stanford cycling training ride led to a partnership that's now bridging the dangerous gap between acute and post-acute care. Amee and her co-founder Pascal—both Kenyans who met thousands of miles from home—shared more than a homeland. They shared mothers fighting cancer and a determination to fix a broken system. What started as rejected startup ideas in Stanford surgeons' offices evolved into WellBeam after one crucial conversation with pancreatic surgeon Dr. Brendan Visser. His frustration was clear: exceptional inpatient care followed by total blindness once patients left the hospital. Fax machines. Phone tag. Patients bouncing back to the ER before anyone knew there was a problem. Now, WellBeam serves as the critical infrastructure connecting hospital EMRs with home health, hospice, and skilled nursing facilities. The result? A 20-30% reduction in readmissions and millions in recovered revenue for physicians doing work they couldn't previously bill. In this episode of Inspiring Women with Laurie McGraw, Amee also discusses: The unexpected value of "having too much fun" at Cambridge and how it shaped her leadership approach Why she left the prestige of investment banking and consulting to work out of a shoebox office in London How catching the "startup bug" at Pavegen prepared her for the healthcare innovation journey The importance of building a village of mentors, especially as a female founder in healthcare Why healthcare's biggest problems aren't glamorous—and why that's exactly where innovation is needed Navigating slow healthcare sales cycles while maintaining startup momentum Leading as a new mother and CEO: ruthless prioritization and trusting your team Chapter Markers 00:54 - Introduction & Background 04:17 - The Stanford Connection & Finding a Co-founder 07:13 - WellBeam's Origin & Solution 11:28 - Business Model & Market Approach 14:06 - Leadership as a Female CEO & New Mother 21:39 - Advice for Aspiring Female Founders Guest & Host Links Connect with Laurie McGraw on LinkedIn Connect with Amee Devani on LinkedIn Connect with Inspiring Women Browse Episodes | LinkedIn | Instagram | Apple | Spotify 

10 Jahre Finanzrocker: Zum Jubiläum gibt's eine inspirierende Hörerfolge mit Max aus München, der offen über seinen Weg zur finanziellen Selbstständigkeit berichtet. Er erzählt, wie u.a. der Podcast sein Denken und Handeln rund ums Geld verändert hat.In dieser besonderen Folge zum zehnten Geburtstag spreche ich mit Max, der seit Jahren begeisterter Hörer ist. Nach einem Wendepunkt 2018 – ausgelöst durch eine Podcast-Folge – hat er seine Finanzen selbst in die Hand genommen, Fehler gemacht, daraus gelernt und Schritt für Schritt ein eigenes Portfolio aufgebaut. Max berichtet von seiner Dividendenstrategie, die ihm 2024 erstmals ein komplettes Bruttomonatsgehalt eingebracht hat.Max gibt Einblicke in sein Leben zwischen München und Leipzig, seine Arbeit im Qualitätsmanagement sowie seine Sicht auf Weiterbildung als Investition ins Humankapital. Seine Erfahrungen mit Immobilien und konkrete Tipps für Einsteiger runden das Gespräch ab. Shownotes:Zum Buch "Der Börse einen Schritt voraus" von Peter Lynch*Zum Buch "Der entspannte Weg zum Reichtum" von Susan Levermann*Zum Buch "Die Essays von Warren Buffett"*Zur großen Jubiläumsfolge aus dem letzten JahrZur 5-Jahres-Folge mit den größten LearningsZur letzten Folge mit Alexander von "Rente mit Dividende"Zur letzten Folge mit Lars Wrobbel zu EinkommensströmenPräsentiert von SailyWenn bei Euch in den Sommerferien ein Urlaub ansteht und ihr unterwegs mobiles Internet braucht, schaut unbedingt beim eSIM-Anbieter Saily vorbei. Mit dem Code „finanzrocker“ bekommt ihr sogar 15% Rabatt auf euren ersten Kauf. Der Rabatt wird über den Link schon gleich abgezogen. Hier geht es direkt zum Angebot von Saily Hosted on Acast. See acast.com/privacy for more information.

Wir sollten über Abtreibungen so reden wie über Knie-OPs, findet der Gynäkologe Andreas Glasner. Im Podcast erklärt er, wie ein Schwangerschaftsabbruch typischerweise abläuft – und welche zwei medizinischen Methoden es gibt. Abtreibung, erklärt.

Es ist eine kuriose Meldung mit einem spannenden Hintergrund: Das KI-Modell Claude 4 hat in einem Laborexperiment versucht, seine Nutzer bei den Behörden zu melden - wegen vermeintlich illegalem Verhalten. Absurde Science-Fiction-Geschichte? Oder ein Blick in die Zukunft? Fritz und Gregor schauen genauer hin: Wie autonom dürfen unsere KI-Modelle sein? Und was können sie vor uns verheimlichen? Über die Hosts: Gregor Schmalzried ist freier Tech-Journalist, Speaker und Berater, u.a. beim Bayerischen Rundfunk. Fritz Espenlaub ist freier Journalist und Ökonom. Er arbeitet unter anderem für den Bayerischen Rundfunk und das Tech-Magazin 1E9. In dieser Folge: 0:00 KI-Vertrauen und Gregors Taxifahrer 2:00 Das Claude-Experiment 10:00 Wenn die KI etwas verheimlicht 19:00 Was kommt da auf uns zu? 28:00 Was haben wir mit KI gemacht? Video-Tools und Netz-Recherche Links: Podcast-Tipp WDR 5 Philosophie https://1.ard.de/philosophisches-radio Claude 4 System Card https://www-cdn.anthropic.com/6be99a52cb68eb70eb9572b4cafad13df32ed995.pdf SnitchBench: Welche KI verpetzt wie oft? https://snitchscript-visualized.vercel.app/ Claude lässt sich nicht böse programmieren https://www.astralcodexten.com/p/claude-fights-back New York Times-Recherche zu Chatbot-Nutzern https://www.nytimes.com/2025/06/13/technology/chatgpt-ai-chatbots-conspiracies.html KI ASMR Videos https://x.com/omooretweets/status/1933938122888470634 Redaktion und Mitarbeit: David Beck, Cristina Cletiu, Chris Eckardt, Fritz Espenlaub, Elisa Harlan, Franziska Hübl, Marie Kilg, Mark Kleber, Gudrun Riedl, Christian Schiffer, Gregor Schmalzried Kontakt: Wir freuen uns über Fragen und Kommentare an kipodcast@br.de. Unterstützt uns: Wenn euch dieser Podcast gefällt, freuen wir uns über eine Bewertung auf eurer liebsten Podcast-Plattform. Abonniert den KI-Podcast in der ARD Audiothek oder wo immer ihr eure Podcasts hört, um keine Episode zu verpassen. Und empfehlt uns gerne weiter!

Snoof, der riesige Zwerg, wandert weiter. Er muss zu Prinzessin Kleinklein, um sich schrumpfen zu lassen. Da begegnet ihm eine Froschfrau. Kann sie etwa zaubern? Aus der OHRENBÄR-Hörgeschichte: Snoofs Reise ins Land der goldenen Pilze (Folge 3 von 7) von Janine Lüttmann. Es liest: Robert Missler. ▶ Mehr Hörgeschichten empfohlen ab 6: https://www.ohrenbaer.de/podcast/empfohlen-ab-6.html ▶ Mehr Infos unter https://www.ohrenbaer.de & ohrenbaer@rbb-online.de

Weiter geht es für Snoof Richtung Süden. Gibt es dort Hilfe für den riesigen Zwerg? Er möchte so gern klein sein. Plötzlich wird er von den singenden Süßholzrasplern umschwärmt. Aus der OHRENBÄR-Hörgeschichte: Snoofs Reise ins Land der goldenen Pilze (Folge 4 von 7) von Janine Lüttmann. Es liest: Robert Missler. ▶ Mehr Hörgeschichten empfohlen ab 6: https://www.ohrenbaer.de/podcast/empfohlen-ab-6.html ▶ Mehr Infos unter https://www.ohrenbaer.de & ohrenbaer@rbb-online.de

Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers.This episode will cover the topic of⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ewing's Sarcoma⁠, from our Pathology section at Orthobullets.com.Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Orthobullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on Social Media:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube

Lauren Henry Brehm joined the podcast to discuss her book The French Court: Essays from One Family's Legacy of Mental Illness and her journey through mental health, family trauma, and personal transformation.Opened up about her grandmother's undiagnosed OCD and its generational impactShared her own suicide attempt and living with Autism Spectrum DisorderReflected on her divorce after 29 years of marriageDescribed her experience in the psychiatric ER and ongoing therapyDiscussed psychiatric medications: Cymbalta, Buspar, Lamictal, TrazodoneMemorable quotes:“I don't want to escape my life, I just don't want it to hurt so much.”“A smile is the shortest distance between two people.”“I learned that I have something to offer everyone.”Purchase Book: https://tinyurl.com/French-Court Thrive With Leo Coaching: If you want to reduce your psychological pain, regain your purpose and forge your own path, go to www.thrivewithleo.com to begin your journey.If you or anyone you know is considering suicide or self-harm, or is anxious, depressed, upset, or needs to talk, there are people who want to help:In the US: Crisis Text Line: Text CRISIS to 741741 for free, confidential crisis counseling. The National Suicide Prevention Lifeline: 1-800-273-8255 or 988The Trevor Project: 1-866-488-7386Outside the US:International Association for Suicide Prevention lists a number of suicide hotlines by country. Click here to find them.

Juror 11, Paula Prado AKA Paula Serageldin AKA Paula Prado Serageldin, a woman of many faces and aliases has been giving interviews hitting all Karen Read's innocence fraud campaign talking points and even referencing a witness that wasn't presented in trial 2. She's a shrewd manipulator from a family of criminals! Let's talk about it!Get access to exclusive content & support the podcast by becoming a Patron today! https://patreon.com/robertaglasstruecrimereportThrow a tip in the tip jar! https://buymeacoffee.com/robertaglassSupport Roberta by sending a donation via Venmo. https://venmo.com/robertaglassBecome a channnel member for custom Emojis, first looks and exclusive streams here: https://youtube.com/@robertaglass/joinShow Notes: Innocence Fraud Watch "(UPDATING) Some Insight Into The Many Faces Of Juror #11 – Conceited Gaslighter, Attention Seeker & Depraved Con-Artist Paula Prado AKA Paula Serageldin AKA Paula Prado Serageldin"- https://theerrorsthatplaguethemiscarriageofjusticemovement.home.blog/2025/06/20/some-insight-into-the-many-faces-of-juror-11-aka-paula-prado-aka-paula-serageldin-aka-paula-prado-serageldin/ Court TV "Karen Read Juror Speaks Out..." - https://youtu.be/1Nn2VUNRTZQ?si=w6C9yIIIMjoVvxS4 Coffee with Karim Ep 45 - https://youtu.be/vq5KF6LjRk8?si=0jgxQaTAFnjWk0WzThank you Patrons!JC, Lizzy D, Elizabeth Drake, Texas Mimi, Barb, Deborah Shults, Debra Ratliff, Stephanie Lamberson, Maryellen Sudol, Mona, Karen Pacini, Jen Buell, Marie Horton, ER, Rosie Grace, B. Rabbit, Sally Merrick, Amanda D, Mary B, Mrs Jones, Amy Gill, Eileen, Wesley Loves Octoberfest, Erin (Kitties1993), Anna Quint, Cici Guteriez, Sandra Loves GatsbyHannna, Christy, Jen Buell, Elle Solari, Carol Cardella, Jennifer Harmon, DoxieMama65, Carol Holderman, Joan Mahon, Marcie Denton, Rosanne Aponte, Johnny Jay, Jude Barnes, JenTheRN, Victoria Devenish, Jeri Falk, Kimberly Lovelace, Penni Miller, Jil, Janet Gardner, Jayne Wallace (JaynesWhirled), Pat Brooks, Jennifer Klearman, Judy Brown, Linda Lazzaro, Suzanne Kniffin, Susan Hicks, Jeff Meadors, D Samlam, Pat Brooks, Cythnia, Bonnie Schoeneman-Dilley, Diane Larsen, Mary, Kimberly Philipson, Cat Stewart, Cindy Pochesci, Kevin Crecy, Renee Chavez, Melba Pourteau, Julie K Thomas, Mia Wallace, Stark Stuff, Kayce Taylor, Alice, Dean, GiGi5, Jennifer Crum, Dana Natale, Bewildered Beauty, Pepper, Joan Chakonas, Blythe, Pat Dell, Lorraine Reid, T.B., Melissa, Victoria Gray Bross, Toni Woodland, Danbrit, Kenny Haines and Toni Natalie.

  Medical TV Shows. From M*A*S*H to St Elsewhere, ER to Scrubs, Call the Midwife to House, Grey's Anatomy to Chicago Med, there have been a wide variety of portrayals of medical care on television over the years. There are some shows that try to […]

Happy Monday! Deborah Larison joins Janice and Deena Talbert today to talk about firearm safety and training during the first hour. If you would like to take classes with Deborah, you can sign up on the  USCCA  website. If you are interested in taking the free class offered to FMR listeners reach out to Janice at FaithMusicRadio.com. During the noon hour Deena and Janice share some thoughts from devotionals written by Amy Vassak and Kimberly Joy. Topics include "God is not an ER surgeon" and "no one has ever regretted giving God their everything."  Janice's books What Do I Have to Lose? Books 1 and 2   are available! The complete set is just $25 for a limited time. Check it out at FaithMusicRadio.com. Today also features A Word of Encouragement with Vicky Mutchler, CW Today with Loretta Walker and Renewing Your Health with Dana Ellison. Be sure to subscribe to this podcast and please share this podcast with your friends so we may be an encouragement to them through the music and programming on Faith Music Radio. Music is brought to you by Faith Music Missions. Learn more here >>> https://www.faithmusicmissions.org Eleven2One Facebook  Eleven2One on Instagram Faith Music Radio is a listener supported Christian station.  

Nach Israel haben jetzt auch die Vereinigten Staaten Atomanlagen des Iran mit speziellen Bomben angegriffen. Die iranische Führung zeigt sich empört und droht mit Vergeltung. Könnte sich der Konflikt also zu einem Flächenbrand in der Region entwickeln? Wie spielt hier die wirtschaftlich wichtige Meerenge, die Straße von Hormuz, mit hinein, war der Iran wirklich kurz vor dem Bau einer Atombombe, und gibt es einen Ausweg aus dem Konflikt? Darüber spricht heute Matthias Wasinger. Er ist Soldat und Militärexperte beim österreichischen Bundesheer.

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

Donald Trump verfolge keine grosse Strategie, die Palette an möglichen Szenarien werde grösser, die Situation von aussen zu analysieren schwieriger. Vieles hänge von einzelnen Personen ab. Sagt der Sicherheitsexperte Oliver Thränert. Er hat sich ein Berufsleben lang mit Atomwaffen befasst. Nach den Angriffen der USA auf iranische Atomanlagen bleiben viele Fragen offen: Was wurde zerstört? Wie reagiert der Iran? Wie seine Verbündeten? Welche Ziele verfolgt Donald Trump? Oliver Thränert leitete 12 Jahre den Thinktank für Sicherheitsstudien an der ETH Zürich und arbeitet weiterhin für die Stiftung Wissenschaft und Politik in Berlin. Das Weltgeschehen sei kurzlebiger geworden, es werde zusehends schwieriger, grössere Linien herauszuarbeiten und von aussen zu analysieren. Oliver Thränert befasst sich seit Jahren mit dem iranischen Atomprogramm. War es ein Fehler, dass Donald Trump das Atomabkommen mit dem Iran gekündigt hat? Wird der Iran aus dem Atomwaffensperrvertragt austreten wie Nordkorea? Der Sicherheitsexperte ist zu Gast im Tagesgespräch bei Karoline Arn.

Sommer 2016. Er zersticht ihre Reifen. Schickt ihr Blumen. Zerkratzt das Auto ihres Freundes. Taucht immer zufällig da auf, wo sie ist. Irgendwann steht er, mitten in der Nacht, in ihrem Haus, am Fuße ihres Bettes. Die 19-jährige Shana Grice weiß, dass sie zur Polizei und Michael Lane anzeigen muss. Doch was, wenn ihr wieder nicht geglaubt wird? Was, wenn sie auf einmal die Böse ist?Heute sprechen wir über Stalking und Mord. Wir reden über eine junge Frau, die vom Opfer zu vermeintlichen Täterin gemacht wird und über einen Mann mit einer dunklen Geschichte. Inhaltswarnungen: Explizite Gewalt, Sexualisierte Gewalt, Coercive Control, Stalking, toxische Beziehung, SuizidOb der Fall gelöst oder ungelöst ist seht ihr ganz unten in der Folgenbeschreibung: N= nicht gelöst, G = Gelöst.SHOWNOTES:Wir kommen nach Rostock!! Yaaay!Tickets für unseren Auftritt bei Thalia in der Universitätsbuchhandlung Rostock findet ihr hier: https://72.reservix.de/p/reservix/event/2427781Vielen Dank an unsere heutigen Werbepartner!Wild: Nachfüllbare Deos, Duschgele und Co findet ihr hier: https://shopwildrefill.com/PUPPIES20Mit unserem Code PUPPIES20 erhaltet ihr 20 % Rabatt auf alle Wild Produkte. Betterhelp:Unsere Hörer:innen erhalten 10 % Rabatt auf den ersten Monat unter BetterHelp.com/PUPPIES.REISE IN DEN TOD Hört rein bei Reise in den Tod, der Podcast, in dem es um Verbrechen geht, die beim Urlaub oder Reisen geschehen sind- exklusiv bei Podimo. Reisefails könnt ihr an folgende Emailadresse schicken: reiseindentod@gmail.comÜber diesen Link könnt ihr Podimo kostenfrei testen: https://podimo.de/reiseindentod - schlagt zu :)Hier findet ihr alle Links zu unseren aktuellen Werbepartnern, Rabatten und Codes:https://linktr.ee/puppiesandcrimeEmpfehlungen:Amandas Empfehlung: Bat Eater and Other Names for Cora Zeng von Kylie Lee BakerMariekes Empfehlung: True BloodSOCIAL MEDIAInstagram: @Puppiesandcrime - https://www.instagram.com/puppiesandcrime/?hl=deTiktok: @puppiesandcrime.podcast - https://www.tiktok.com/@puppiesandcrime.podcastFacebook: https://www.facebook.com/PuppiesandCrimeEmail: puppiesandcrime@gmail.com------- G --------- Hosted on Acast. See acast.com/privacy for more information.

Der riesige Zwerg Snoof packt seine Sachen. Er will zu Prinzessin Kleinklein ins Land der goldenen Pilze. Sie muss ihn schrumpfen! Unterwegs kommt er am blaublütigen Baum vorbei. Aus der OHRENBÄR-Hörgeschichte: Snoofs Reise ins Land der goldenen Pilze (Folge 2 von 7) von Janine Lüttmann. Es liest: Robert Missler. ▶ Mehr Hörgeschichten empfohlen ab 6: https://www.ohrenbaer.de/podcast/empfohlen-ab-6.html ▶ Mehr Infos unter https://www.ohrenbaer.de & ohrenbaer@rbb-online.de

Snoof ist traurig. Im Dorf ist er größte Zwerg. Er wächst weiter! Die anderen nennen ihn Koloss. Lieber wäre er klein. Kann Prinzessin Kleinklein im Land der goldenen Pilze helfen? Aus der OHRENBÄR-Hörgeschichte: Snoofs Reise ins Land der goldenen Pilze (Folge 1 von 7) von Janine Lüttmann. Es liest: Robert Missler. ▶ Mehr Hörgeschichten empfohlen ab 6: https://www.ohrenbaer.de/podcast/empfohlen-ab-6.html ▶ Mehr Infos unter https://www.ohrenbaer.de & ohrenbaer@rbb-online.de

Am 22.6.1745 sticht Bonnie Prince Charlie in See, um mit den Jakobiten den britischen Thron zurückzuerobern. Er scheitert, flieht - und überlässt seine Landsleute der Verfolgung. Von Edda Dammmüller.

Hermann Bühlbecker ist gerade in den Endzügen seiner Promotion, als er eine Entscheidung treffen muss: Steige ich in das marode Familienunternehmen ein oder lasse ich zu, dass es verkauft wird? Er entscheidet sich für den Einstieg – und übernimmt kurze Zeit später die Führung beim Printen-Hersteller Lambertz aus Aachen, dessen Geschäft er in den nächsten Jahren immer weiter ausbaut und um Lebkuchen, Stollen und Bio-Kekse ergänzt. Von der Fast-Pleite zum Unternehmen mit mehr als 600 Millionen Euro Umsatz: Wie das möglich war, erzählt Hermann Bühlbecker im OMR Podcast.

"Da kommt der Koloss", hört Zwerg Snoof jedes Mal, wenn er durchs Dorf geht. Und immer gibt es Ärger, weil er an die Wände seiner Hütte stößt und der Lärm die anderen weckt. Er hat ein Problem: Er ist der größte Zwerg und wächst weiter! Lieber wäre er klein. Ob die Prinzessin im Land der goldenen Pilze ihn schrumpfen lassen kann? Snoof macht sich auf den Weg. Alle 7 Folgen der OHRENBÄR-Hörgeschichte: Snoofs Reise ins Land der goldenen Pilze von Janine Lüttmann. Es liest: Robert Missler. ▶ Mehr Hörgeschichten empfohlen ab 6: https://www.ohrenbaer.de/podcast/empfohlen-ab-6.html ▶ Mehr Infos unter https://www.ohrenbaer.de & ohrenbaer@rbb-online.de

Munaf Manji and Griffin Warner break down MLB Saturday from a betting perspective. They open by focusing on the early matchup between the Tigers and Rays. Both lean toward Tampa Bay, highlighting Ryan Pepio's strong recent form—3.11 ERA over 15 starts and 11 strikeouts in his last outing. Pepio's underappreciated market value and Detroit's surprising top MLB record are discussed, with consensus on Rays at -120. For Orioles vs Yankees, Clark Schmidt is praised for allowing only three earned runs across four recent starts. Zach Eflin, although historically solid against the Yankees, struggled in his last outing. Both lean toward Orioles as underdogs and prefer the under 9.5 total due to Yankee Stadium's scoring tendencies. In Reds vs Cardinals, Sonny Gray's strong home record (5-1, 2.85 ERA) contrasts with his struggles against Cincinnati (4.70 ERA). Without a Reds starter listed, Griffin leans toward the Reds due to line inflation. Munaf might back St. Louis if run line odds are favorable. Seattle at Chicago is discussed with attention to wind's effect at Wrigley Field. Emerson Hancock has pitched well recently, but the Mariners lost his last four starts due to poor run support. Cade Horton's 2.70 ERA at home is noted. Both hosts await wind direction before betting, with a potential over expected. In Milwaukee vs Minnesota, Quintana's inconsistency and walk rate are flagged, while Richardson is labeled a weak rotation fill-in. Despite concerns, both see value in Brewers at plus money. For White Sox vs Blue Jays, Berríos' strong history against Chicago (14-6, 3.16 ERA) supports Munaf's best bet: Jays -1.5 run line at -105. Griffin notes the White Sox's poor weekend performances and questions their motivation. Rangers vs Pirates features concerns around Kumar Rocker's splits (15.09 ERA on road) and Mitch Keller's unreliable late innings. Despite bad offenses, both expect a high-scoring game. The Braves visit the Marlins in a matchup where Grant Holmes is riding a 15-strikeout game. Yuri Perez has struggled mightily vs Atlanta. Both favor a Braves team total over as their offense heats up. Kansas City faces San Diego with Dylan Cease showing volatility. Royals are praised for recent form, including a sweep of Texas, and bullpen strength. Hosts lean Royals ML and under in the first five innings. Mets vs Phillies highlights Griffin Canning's struggles—10 earned runs in his last two outings—against Mick Abel's potential. Philadelphia is seen as cheap at -112, with both supporting the home side. In Arizona vs Colorado, Merrill Kelly's dominance (7-0, 1.60 ERA vs Rockies since 2022) is emphasized, including a 2.03 ERA at Coors. Yet due to rising temperatures and Palmquist's late fade, they suggest betting over. Astros vs Angels is discussed with Walter's solid last start (6.2 IP, 1 ER, 9 K) and Soriano's overall reliability. However, the Angels' 1-5 record vs lefties at home tilts the pick to Astros at -110. Guardians vs A's offers little confidence. Luis Ortiz's high walk rate and Mitch Spence's Triple-A quality result in a lean toward the over and a mild interest in the A's if plus money improves. Nationals vs Dodgers sees Jake Irvin's night game struggles (5.16 ERA) and Dustin May's inconsistency. The hosts recommend Dodgers team total over or full game over. Lastly, Boston visits San Francisco with Brayan Bello consistent and Landen Roop unproven. While Giants are tough at home, the under 7.5 is the preferred angle due to low scoring projections. Griffin's best bet is Rays ML behind Pepio, while Munaf backs Berríos and Toronto on the run line. The episode closes with promo code RBI20 for a discounted betting package. Learn more about your ad choices. Visit megaphone.fm/adchoices

"Er durchbrach die Grenzen des Himmels", das steht auf dem Grab von William Herschel geschrieben. Der in Hannover gebürtige Herschel ist uns als Musiker bekannt, aber berühmt wurde er als Astronom. Er entdeckte Sternenbilder und zeigte die auch seinen Zeitgenossen. Der Blick ins Weltall konnte allerdings wahrhaft schockierend sein. Davon zeugt ein wichtiges musikalisches Dokument. "Die Schöpfung". Bevor Joseph Haydn die zu komponieren begann, erlebte er diesen Schock - den Blick in die Ewigkeit.

Munaf Manji and Griffin Warner break down MLB Saturday from a betting perspective. They open by focusing on the early matchup between the Tigers and Rays. Both lean toward Tampa Bay, highlighting Ryan Pepio's strong recent form—3.11 ERA over 15 starts and 11 strikeouts in his last outing. Pepio's underappreciated market value and Detroit's surprising top MLB record are discussed, with consensus on Rays at -120. For Orioles vs Yankees, Clark Schmidt is praised for allowing only three earned runs across four recent starts. Zach Eflin, although historically solid against the Yankees, struggled in his last outing. Both lean toward Orioles as underdogs and prefer the under 9.5 total due to Yankee Stadium's scoring tendencies. In Reds vs Cardinals, Sonny Gray's strong home record (5-1, 2.85 ERA) contrasts with his struggles against Cincinnati (4.70 ERA). Without a Reds starter listed, Griffin leans toward the Reds due to line inflation. Munaf might back St. Louis if run line odds are favorable. Seattle at Chicago is discussed with attention to wind's effect at Wrigley Field. Emerson Hancock has pitched well recently, but the Mariners lost his last four starts due to poor run support. Cade Horton's 2.70 ERA at home is noted. Both hosts await wind direction before betting, with a potential over expected. In Milwaukee vs Minnesota, Quintana's inconsistency and walk rate are flagged, while Richardson is labeled a weak rotation fill-in. Despite concerns, both see value in Brewers at plus money. For White Sox vs Blue Jays, Berríos' strong history against Chicago (14-6, 3.16 ERA) supports Munaf's best bet: Jays -1.5 run line at -105. Griffin notes the White Sox's poor weekend performances and questions their motivation. Rangers vs Pirates features concerns around Kumar Rocker's splits (15.09 ERA on road) and Mitch Keller's unreliable late innings. Despite bad offenses, both expect a high-scoring game. The Braves visit the Marlins in a matchup where Grant Holmes is riding a 15-strikeout game. Yuri Perez has struggled mightily vs Atlanta. Both favor a Braves team total over as their offense heats up. Kansas City faces San Diego with Dylan Cease showing volatility. Royals are praised for recent form, including a sweep of Texas, and bullpen strength. Hosts lean Royals ML and under in the first five innings. Mets vs Phillies highlights Griffin Canning's struggles—10 earned runs in his last two outings—against Mick Abel's potential. Philadelphia is seen as cheap at -112, with both supporting the home side. In Arizona vs Colorado, Merrill Kelly's dominance (7-0, 1.60 ERA vs Rockies since 2022) is emphasized, including a 2.03 ERA at Coors. Yet due to rising temperatures and Palmquist's late fade, they suggest betting over. Astros vs Angels is discussed with Walter's solid last start (6.2 IP, 1 ER, 9 K) and Soriano's overall reliability. However, the Angels' 1-5 record vs lefties at home tilts the pick to Astros at -110. Guardians vs A's offers little confidence. Luis Ortiz's high walk rate and Mitch Spence's Triple-A quality result in a lean toward the over and a mild interest in the A's if plus money improves. Nationals vs Dodgers sees Jake Irvin's night game struggles (5.16 ERA) and Dustin May's inconsistency. The hosts recommend Dodgers team total over or full game over. Lastly, Boston visits San Francisco with Brayan Bello consistent and Landen Roop unproven. While Giants are tough at home, the under 7.5 is the preferred angle due to low scoring projections. Griffin's best bet is Rays ML behind Pepio, while Munaf backs Berríos and Toronto on the run line. The episode closes with promo code RBI20 for a discounted betting package. Learn more about your ad choices. Visit megaphone.fm/adchoices